![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
|
|
|
IDWeek 2018, October 3-7, 2018, San Francisco
Chloe Orkin1, Kathleen E. Squires2,7, Jean-Michel Molina3, Paul E. Sax4, Wing-Wai Wong5, Otto Sussmann6, Gina Lin7, Sushma Kumar7, George J. Hanna7, Carey Hwang7, Elizabeth Martin7, Hedy Teppler7 on behalf of the DRIVE-AHEAD study team
![1005181](../images%20/100618/1000618-3/1005181.gif)
![1005182](../images%20/100618/1000618-3/1005182.gif)
![1005183](../images%20/100618/1000618-3/1005183.gif)
![1005184](../images%20/100618/1000618-3/1005184.gif)
![1005185](../images%20/100618/1000618-3/1005185.gif)
![1005186](../images%20/100618/1000618-3/1005186.gif)
![1005187](../images%20/100618/1000618-3/1005187.gif)
![1005188](../images%20/100618/1000618-3/1005188.gif)
![1005189](../images%20/100618/1000618-3/1005189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|